Bladder Cancer: Discussions

ASCO GU 2022

Neoadjuvant therapy in UTUC: Good options for selected…

P. J. Goebell, M.-O. Grimm, J. Bellmunt, P. Grivas, S. Chowdhury

ATLANTIS, BAYOU, MEET-URO12

ASCO GU 2022

Role of PARPi in urothelial cancer

P. J. Goebell, M.-O. Grimm, J. Bellmunt, P. Grivas, S. Chowdhury

TROPHY-U-001, EV-103

ASCO GU 2022

ADC in bladder cancer: defining the future!

P. J. Goebell, M.-O. Grimm, J. Bellmunt, P. Grivas, S. Chowdhury

Bladder Cancer: 100 Seconds

BAYOU, ATLANTIS

ASCO GU 2022

PARPi in urothelial cancer: DFS advantage for the DDR+,…

Tom Powles, MD

DS8201-A-U105

ASCO GU 2022

ADCs will be step-changing in urothelial cancers

Simon Chowdhury, MD

ATLANTIS, BAYOU, MEET-URO12

ASCO GU 2022

Not practice changing, but hypothesis generating.

Petros Grivas, MD

KEYNOTE-365

ASCO GU 2022

Ongoing immunotherapy innovation for mCRPC

Neal Shore, MD

TITAN-TCC

ASCO GU 2022

IO escalation results in improved response in met. TCC.

Marc-Oliver Grimm, MD

ASCO GU 2022

Patient selection for bladder preservation

Petros Grivas, MD

JAVELIN Bladder 100

ASCO GU 2022

Mature data confirm efficacy of maintenance avelumab as…

Tom Powles, MD

ASCO GU 2022

Exciting data supports trimodality therapy

Axel Merseburger, MD

DS8201-A-U105; RC48-C014

ASCO GU 2022

HER2 ERBB2 – entering precision oncology

Philipp Ivanyi, MD

TROPHY-U-001, DS8201

ASCO GU 2022

ADC shape the therapy landscape in urothelial cancer

Petros Grivas, MD

CheckMate-274

ASCO GU 2022

Patient selection for adjuvant Nivolumab (TPS vs. CPS)

Marc-Oliver Grimm, MD

JAVELIN Bladder 100

ASCO GU 2022

Follow-up data confirm OS benefit across subgroups

Petros Grivas, MD

Prostate Cancer: Discussions

PROpel; MAGNITUDE

ASCO GU 2022

Do we need testing? Which biomarkers are of relevance?

A. Bjartell, N. Shore, A. Merseburger, M.-O. Grimm, G. Morgan; S. Chowdhury, E. Efstathiou

PRESIDE

ASCO GU 2022

Enza beyond progression? Practice changing or not?

A. Bjartell, N. Shore, A. Merseburger, M.-O. Grimm, G. Morgan; S. Chowdhury, E. Efstathiou

ARASENS

ASCO GU 2022

Triplet vs. doublet: Which patients should we consider?

A. Bjartell, N. Shore, A. Merseburger, M.-O. Grimm, G. Morgan; S. Chowdhury, E. Efstathiou

ASCO GU 2022

The future of genetic testing. Somatic vs. germline?…

A. Bjartell, N. Shore, A. Merseburger, M.-O. Grimm, G. Morgan; S. Chowdhury, E. Efstathiou

VISION; PSMAfore; PSMAddition; TheraP

ASCO GU 2022

Theranostics – Presence and future: Vision, PSMAfore,…

A. Bjartell, N. Shore, A. Merseburger, M.-O. Grimm, G. Morgan; S. Chowdhury, E. Efstathiou

Prostate Cancer: 100 Seconds

ASCO GU 2022

Is biomarker development taking a back seat in prostate…

Eleni Efstathiou, MD

DS7300

ASCO GU 2022

Exciting new compound for mCRPC

Simon Chowdhury, MD

MAGNITUDE, PROpel

ASCO GU 2022

PROpel & Magnitude: who wins the race?

Axel Merseburger, MD

ASCO GU 2022

How to improve PSMA based radioligand therapy

Anders Bjartell, MD

PROpel

ASCO GU 2022

Should we use arbiraterone and olaparib as 1st line…

Gil Morgan, MD

HERO

ASCO GU 2022

Subgroup analyses confirm the importance of oral daily…

Neal Shore, MD

ASCO GU 2022

New therapies and molecular targets in prostate cancer

Anders Bjartell, MD

SPARTAN & TITAN

ASCO GU 2022

PSA response correlates with OS and benefits in QoL

Simon Chowdhury, MD

PRESIDE

ASCO GU 2022

PRESIDE indicates benefit of continuation ENZA + ADT

Anders Bjartell, MD

MiCheck

ASCO GU 2022

The need for biomarker panels in biopsy decision making

Neal Shore, MD

PROpel MAGNITUDE

ASCO GU 2022

Where do PROpel and Magnitude agree?

Eleni Efstathiou, MD

Arasens

ASCO GU 2022

Addition of darolutamide improves OS in met.…

Gil Morgan, MD

ASCO GU 2022

The importance of conducting HCRA

Neal Shore, MD

PRESIDE

ASCO GU 2022

Is the dual hormone-backbone the future?

Axel Merseburger, MD

ARASENS

ASCO GU 2022

Triplet-therapy as a novel treatment option

Axel Merseburger, MD

ARASENS

ASCO GU 2022

DARO in triplet therapy for CRPC

Anders Bjartell, MD

ARASENS

ASCO GU 2022

Is docetaxel still needed for hormone sensitive mCRPC?

Elena Efstathiou, MD

Magnitude

ASCO GU 2022

Should we use arbiraterone and niraparib as 1st line…

Gil Morgan, MD

PROpel; Magnitude

ASCO GU 2022

HRR testing: MAGNITUDE vs. PROpel

Gil Morgan, MD

TheraP ANZUP 1603

ASCO GU 2022

PSMA and FDG PET as biomarkers for response to LuPSMA

Anders Bjartell, MD

Renal Cell Carcinoma: Discussions

NeoAvAx

ASCO GU 2022

Neoadjuvant IO+TKI Treatment: We need more data on…

T. Powles, H. Hammers, M.-O. Grimm, S. Chowdhury, P. Ivanyi

Keynote-564

ASCO GU 2022

Adjuvant PD1 Therapy confirms significant benefit for…

T. Powles, H. Hammers, M.-O. Grimm, S. Chowdhury, P. Ivanyi

TITAN-RCC, HCRN GU16-260

ACO GU 2022

Treatment options following adjuvant PD1 Therapy:…

T. Powles, H. Hammers, M.-O. Grimm, S. Chowdhury, P. Ivanyi

CheckMate 9ER

ASCO GU 2022

Thoughts on first line treatment options following ASCO…

T. Powles, H. Hammers, M.-O. Grimm, S. Chowdhury, P. Ivanyi

Renal Cell Carcinoma: 100 seconds

KEYNOTE-564

ASCO GU 2022

Consistent OS benefit confirmed. Consider overtreatment…

Tom Powles, MD

KEYNOTE-564

ASCO GU 2022

Adjuvant Pembroluzimab update in kidney cancer

Hans Hammers, MD

NeoAvAx

ASCO GU 2022

Update in neoadjuvant therapy for kidney cancer

Sumanta Kumar Pal, MD

CaboCHECK; CABOSEQ

ASCO GU 2022

Data gap in 2nd line RCC: what’s new?

Philipp Ivanyi, MD

ASCO GU 2022

Microbioma modification and checkpoint inhibition

Philipp Ivanyi, MD

KEYNOTE 564

ASCO GU 2022

Update in adjuvant therapy for kidney cancer

Sumanta Kumar Pal, MD

CheckMate9ER; CABOSEQ

ASCO GU 2022

Frontline treatment of metastatic kidney cancer

Sumanta Kumar Pal, MD

CheckMate 9ER; CheckMate 214

ASCO GU 2022

CheckMate final OS Follow Up and health related QoL

Philipp Ivanyi, MD

HCRN GU16-260

ASCO GU 2022

Nivo montoherapy followed by Nivi-Ipi resuce

Hans Hammers, MD

NeoAvAx

ASCO GU 2022

Neoadjuvant avelumab/axitinib - NeoAvAx

Hans Hammers, MD